降压治疗对原发性高血压患者血浆Fib、t-PA及PAI-1浓度变化的影响

目的：研究原发性高血压（EH）患者血液纤维系统改变及降压药物治疗对其影响,探讨EH患者血栓前状态（PTS）发生机制及降压治疗减少血栓事件的机理。方法：用酶联免疫吸附（ELISA）竞争及双抗体夹心法对30例EH患者分别于降压治疗前后测定外周静脉血浆纤维蛋白原（Fib）、组织型纤溶酶原激活物（t-PA）及组织型纤溶酶原激活物抑制物-1（PAI-1）浓度变化,并与30例健康体检者相比较。结果：EH患者降压治疗前血浆Fib,t-PA及PAI-1浓度比正常对照组明显升高;福辛普利与贝尼地平联合降压治疗6周后与治疗前相比明显降低。结论：EH患者体内存在PTS与纤维系统低下有关,福辛普利与贝尼地平联合降压治疗能改善PTS。

The Effects of Antihypertensives in the Changes of the Concentration of Plasma fibriongen,tissue-type plasminogen activator and Plasminogen activator inhibitor-1 in Patients with Elementary Hypertension

Objective：To study the changes of fibrinolysis patients with essential hypertension （EH） and the effects of antihypertensives in it ,and explore the mechanism of prothrombotie state （PTS） in EH and the possible reason of antihypertensive treatment on decreasing the accident of thrombosis. Methods ：ELISA was used to measure plasma fibriongen （Fib）,tissue-type plasminogen activator（t-PA） and Plasminogen activator inhibitor-1 （PAI-1） in 30 patients with EH before and after antihypertensive treatment for 6 weeks, Serum levels of Fib,tPA and PAI-1 were compared with those in 30 healthy subjects. Results：The concentration of plasma Fib,t-PA and PAI-1 in EH group were significantly higher than that in control group which also significantly lowered after 6 weeks treatment with ACEI and CCB. Conclusion：PTS in EH is relevant to hypofibrinolysis and the combining treatment of ACEI and CCB can release PTS in patients with EH.